Logo do repositório
 
Publicação

Gut microbiota profile of COVID-19 patients

dc.contributor.authorNobre, José Guilherme
dc.contributor.authorDelgadinho, Mariana
dc.contributor.authorSilva, Carina
dc.contributor.authorMendes, Joana
dc.contributor.authorMateus, Vanessa
dc.contributor.authorRibeiro, Edna
dc.contributor.authorCosta, Diogo Alpuim
dc.contributor.authorLopes, Miguel
dc.contributor.authorPedroso, Ana Isabel
dc.contributor.authorTrigueiros, Frederico
dc.contributor.authorRodrigues, Maria Inês
dc.contributor.authorde Sousa, Cristina Lino
dc.contributor.authorBrito, Miguel
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblFrontiers Research Foundation
dc.date.accessioned2022-12-13T22:18:10Z
dc.date.available2022-12-13T22:18:10Z
dc.date.issued2022-11-22
dc.descriptionFunding Information: The authors acknowledge financial support from Instituto Politécnico de Lisboa that supported this project with the grant Microcovid. This project was also partially supported by FCT/MCTES (UIDB/05608/2020 and UIDP/05608/2020). Publisher Copyright: Copyright © 2022 Nobre, Delgadinho, Silva, Mendes, Mateus, Ribeiro, Costa, Lopes, Pedroso, Trigueiros, Rodrigues, de Sousa and Brito.
dc.description.abstractBackground: Gut microbiota is intrinsically associated with the immune system and can promote or suppress infectious diseases, especially viral infections. This study aims to characterize and compare the microbiota profile of infected patients with SARS-CoV-2 (milder or severe symptoms), non-infected people, and recovered patients. This is a national, transversal, observational, multicenter, and case–control study that analyzed the microbiota of COVID-19 patients with mild or severe symptoms at home, at the hospital, or in the intensive care unit, patients already recovered, and healthy volunteers cohabiting with COVID-19 patients. DNA was isolated from stool samples and sequenced in a NGS platform. A demographic questionnaire was also applied. Statistical analysis was performed in SPSS. Results: Firmicutes/Bacteroidetes ratios were found to be significantly lower in infected patients (1.61 and 2.57) compared to healthy volunteers (3.23) and recovered patients (3.89). Furthermore, the microbiota composition differed significantly between healthy volunteers, mild and severe COVID-19 patients, and recovered patients. Furthermore, Escherichia coli, Actinomyces naeslundii, and Dorea longicatena were shown to be more frequent in severe cases. The most common COVID-19 symptoms were linked to certain microbiome groups. Conclusion: We can conclude that microbiota composition is significantly affected by SARS-CoV-2 infection and may be used to predict COVID-19 clinical evolution. Therefore, it will be possible to better allocate healthcare resources and better tackle future pandemics.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1114105
dc.identifier.doi10.3389/fmicb.2022.1035422
dc.identifier.issn1664-302X
dc.identifier.otherPURE: 48289937
dc.identifier.otherPURE UUID: fc752163-987b-4226-a1c3-825bfef8e411
dc.identifier.otherScopus: 85143310997
dc.identifier.urihttp://hdl.handle.net/10362/146185
dc.identifier.urlhttps://www.scopus.com/pages/publications/85143310997
dc.language.isoeng
dc.peerreviewedyes
dc.subjectCOVID-19
dc.subjectdysbiosis
dc.subjectmicrobiome
dc.subjectmicrobiota
dc.subjectnext generation sequencing
dc.subjectprognosis
dc.subjectrisk stratification
dc.subjectMicrobiology
dc.subjectMicrobiology (medical)
dc.subjectSDG 3 - Good Health and Well-being
dc.titleGut microbiota profile of COVID-19 patientsen
dc.title.subtitlePrognosis and risk stratification (MicroCOVID-19 study)en
dc.typejournal article
degois.publication.titleFrontiers in Microbiology
degois.publication.volume13
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
fmicb_13_1035422.pdf
Tamanho:
1.06 MB
Formato:
Adobe Portable Document Format